- Home
- HTO vs VCEL Comparison
HTO vs VCEL Comparison
Compare HTO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | VCEL |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | HTO | VCEL |
|---|---|---|
| Price | $48.83 | $37.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $58.00 | $57.50 |
| AVG Volume (30 Days) | 422.2K | ★ 599.1K |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | 14.49 | ★ 236.54 |
| EPS | ★ 3.17 | 0.25 |
| Revenue | ★ $804,224,000.00 | $258,716,999.00 |
| Revenue This Year | $9.75 | $17.86 |
| Revenue Next Year | $8.19 | $18.55 |
| P/E Ratio | ★ $15.38 | $152.71 |
| Revenue Growth | 11.39 | ★ 14.05 |
| 52 Week Low | $43.75 | $29.24 |
| 52 Week High | $57.17 | $63.00 |
Technical Indicators
Market Signals| Indicator | HTO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 51.36 |
| Support Level | $48.67 | $35.53 |
| Resistance Level | $50.45 | $38.09 |
| Average True Range (ATR) | 1.23 | 1.35 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 59.27 | 71.10 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.